Meiji Yasuda Asset Management Co Ltd. Reduces Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Meiji Yasuda Asset Management Co Ltd. trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,005 shares of the medical equipment provider’s stock after selling 320 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Zimmer Biomet were worth $317,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth about $25,000. Dunhill Financial LLC boosted its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $35,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $39,000. Finally, OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $40,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE:ZBH opened at $112.21 on Friday. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $131.61. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $107.18 and a two-hundred day moving average of $107.01. The stock has a market cap of $22.34 billion, a P/E ratio of 25.22, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company earned $2.20 earnings per share. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Barclays dropped their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Royal Bank of Canada dropped their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.